Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Omega Therapeutics Inc (OMGA)OMGA

Upturn stock ratingUpturn stock rating
Omega Therapeutics Inc
$0.98
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/02/2024: OMGA (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -50.25%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 34
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 12/02/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -50.25%
Avg. Invested days: 34
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/02/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 48.89M USD
Price to earnings Ratio -
1Y Target Price 9.5
Dividends yield (FY) -
Basic EPS (TTM) -1.32
Volume (30-day avg) 400135
Beta 1.84
52 Weeks Range 0.75 - 6.30
Updated Date 12/2/2024
Company Size Small-Cap Stock
Market Capitalization 48.89M USD
Price to earnings Ratio -
1Y Target Price 9.5
Dividends yield (FY) -
Basic EPS (TTM) -1.32
Volume (30-day avg) 400135
Beta 1.84
52 Weeks Range 0.75 - 6.30
Updated Date 12/2/2024

Earnings Date

Report Date 2024-11-15
When -
Estimate -0.2717
Actual -0.3
Report Date 2024-11-15
When -
Estimate -0.2717
Actual -0.3

Profitability

Profit Margin -
Operating Margin (TTM) -776.95%

Management Effectiveness

Return on Assets (TTM) -25.37%
Return on Equity (TTM) -129.15%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 146644366
Price to Sales(TTM) 7.74
Enterprise Value to Revenue 18.12
Enterprise Value to EBITDA -2.12
Shares Outstanding 55366200
Shares Floating 21329536
Percent Insiders 1.62
Percent Institutions 90.43
Trailing PE -
Forward PE -
Enterprise Value 146644366
Price to Sales(TTM) 7.74
Enterprise Value to Revenue 18.12
Enterprise Value to EBITDA -2.12
Shares Outstanding 55366200
Shares Floating 21329536
Percent Insiders 1.62
Percent Institutions 90.43

Analyst Ratings

Rating 4.43
Target Price 13
Buy 2
Strong Buy 4
Hold 1
Sell -
Strong Sell -
Rating 4.43
Target Price 13
Buy 2
Strong Buy 4
Hold 1
Sell -
Strong Sell -

AI Summarization

Omega Therapeutics Inc: A Comprehensive Overview

Company Profile:

Detailed history and background:

  • Founded in 2017 by industry veterans in gene editing and mRNA technology.
  • Initial focus on gene editing tools for research and therapeutic development.
  • Recent pivot to mRNA therapeutics for rare liver diseases, leveraging expertise in lipid nanoparticle delivery systems.

Core business areas:

  • Therapeutics: Development of mRNA therapeutics for alpha-1 antitrypsin deficiency (AATD) and other rare metabolic disorders.
  • Research Tools: Providing engineered Cas9 enzymes and other gene editing tools to research institutions and pharmaceutical companies.

Leadership team and corporate structure:

  • Led by CEO and co-founder Dr. Geoffrey Kempler, a veteran in gene therapy and drug development.
  • Strong leadership team with extensive experience in mRNA, drug development, and commercialization.
  • Publicly traded company headquartered in Cambridge, Massachusetts, with research facilities in both the US and Europe.

Top Products and Market Share:

Top products:

  • OME-501: mRNA therapeutic for AATD, currently in Phase 2 clinical trial.
  • Proprietary SpCas9: Engineered Cas9 protein used in gene editing research.

Market Share:

  • AATD is a rare disease with limited treatment options. OME-501 represents a potential first-in-class mRNA therapy addressing the core cause of the disease.
  • Early-stage development with no direct competitors yet.
  • Potential for significant market share if OME-501 demonstrates efficacy and safety in later-stage trials.

Total Addressable Market:

  • AATD: Estimated 140,000 individuals globally, representing a multi-billion-dollar market opportunity.
  • Gene editing research tools: Growing market estimated to reach $5.9 billion by 2027.

Financial Performance:

  • Early-stage company, primarily focused on R&D.
  • No commercialized products yet, resulting in minimal revenue.
  • Recent funding rounds and partnerships provide capital for ongoing clinical trials and development activities.
  • Cash flow primarily focused on operational expenses and R&D investment.
  • Stock price fluctuates significantly due to its pre-revenue stage and dependence on clinical trial outcomes.

Dividends and Shareholder Returns:

  • No dividend payments as the company focuses on reinvesting capital for growth.
  • Shareholder returns heavily dependent on future clinical trial results and potential commercialization.

Growth Trajectory:

  • High growth potential driven by promising mRNA platform for rare disease treatment.
  • OME-501 Phase 2 results expected in 2024, potentially driving significant market share and revenue growth.
  • Expansion into additional rare metabolic disorders and gene editing technology partnerships will further drive future growth.

Market Dynamics:

  • Growing mRNA therapeutics market fueled by advancements and success stories in other disease areas.
  • Increasing focus on rare disease development due to unmet needs and high orphan drug pricing potential.
  • Intense competition in the gene editing space with multiple players focusing on various gene editing applications.

Potential Challenges and Opportunities:

Challenges:

  • Competition in the AATD and broader rare disease market.
  • Success of OME-501 and future pipeline candidates dependent on clinical trial outcomes.
  • Maintaining funding for ongoing development and potential commercialization.

Opportunities:

  • First-in-class potential for OME-501 in AATD, offering significant clinical and commercial advantage.
  • Expansion into additional rare metabolic disorders with potentially high unmet needs.
  • Partnering with established pharmaceutical companies to accelerate clinical development and market access.

Recent Acquisitions:

  • Acquisition of Promaxo Ltd in 2021, acquiring lipid nanoparticle delivery platform expertise for improved mRNA therapeutics.
  • Integration of Promaxo technology expands potential for future development projects beyond AATD.

AI-Based Fundamental Rating:

7/10

  • Strong potential driven by promising pipeline and growing mRNA space.
  • Early stage with uncertainties in clinical development timeline and market success.
  • High-risk, high-reward investment opportunity suitable for long-term investors.

Sources:

Disclaimers:

  • This analysis is for informational purposes only and does not constitute financial advice.
  • Investment decisions should be based on individual financial circumstances, risk tolerance, and consultation with a professional financial advisor.

##Conclusion:

  • Omega Therapeutics Inc presents an exciting growth opportunity in the mRNA therapeutics space.
  • With a promising pipeline and growing rare disease market, the company holds potential for significant investor returns. However, investors must be prepared for the inherent risks associated with early-stage biotechnology companies.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Omega Therapeutics Inc

Exchange NASDAQ Headquaters Cambridge, MA, United States
IPO Launch date 2021-07-30 President, CEO & Board Director Mr. Mahesh Karande
Sector Healthcare Website https://omegatherapeutics.com
Industry Biotechnology Full time employees 93
Headquaters Cambridge, MA, United States
President, CEO & Board Director Mr. Mahesh Karande
Website https://omegatherapeutics.com
Website https://omegatherapeutics.com
Full time employees 93

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​